BLOG: Good outcomes seen in recently approved RxSight IOL

A recent and exciting FDA approval for the RxSight Light Adjustable Lens and Light Delivery Device has been achieved.

This IOL, which was formally called the Calhoun lens (and has been in development for years), is a silicone-based three-piece IOL that contains zones of photosensitive molecules. These photosensitive zones allow for predicable changes to the shape of the lens to be made with a specialized UV source and allow for a titration of refractive error postoperatively.

These shape changes can adjust for myopia, hyperopia and astigmatism, all within about a 2-D range. Refractive titrations are followed by a “locking-in procedure,” where the entire lens is polymerized, exhausting any residual photosensitive molecules and locking the refraction in.

Tune-ups and lock-ins are performed within the first month postoperatively. During this period, the patient is required to wear UV-protecting glasses to prevent unwanted polymerization until the lens has been “locked.” The entire goal is to improve refractive outcomes for emmetropic targets, but multifocal treatments are also feasible, although off-label.

While light adjustable IOLs do not always achieve plano sphere outcomes, the average final postoperative refractive error is less when compared to standard IOLs.

There are limitations on patients in whom it can be used, as there is a minimum pupil size, and the lens is contraindicated in any patient who is on a medication that may increase sensitivity to UV radiation.

Despite these limitations, the technology is exciting. In particular, we think this may end up being a great option for people who have had previous refractive surgery to ensure more accuracy with refractive outcomes.

Pricing of the lens and light delivery system are unavailable at this time, but expect to hear more about this interesting technology.